Extract according to the product.
Some data in kidney disease, mostly in China.
View the study (meta-analysis) →Possible immunomodulatory effect; weak evidence in humans.
⏱ 3 min read
Astragalus, or huang qi, is Astragalus membranaceus, a legume native to northern China and Mongolia whose root has been used in traditional Chinese medicine for more than 2,000 years as an immune tonic, adaptogen, and "strengthener of qi" (vital energy); it is one of the pillars of classical Chinese herbal medicine, present in hundreds of traditional formulas and regarded as one of the main tonics of the immune system, an indication that modern Western research has begun to support with increasingly solid clinical and mechanistic data.
The identified active compounds are several: astragalosides (especially astragaloside IV, the most studied), complex polysaccharides with immunomodulatory activity, flavonoids (especially formononetin and calycosin), and a compound of particular interest for longevity research: cycloastragenol, a documented telomerase activator, the enzyme that maintains telomere length and whose activation has been the subject of intense research as a possible cellular anti-aging target.
The indication with the most widespread clinical use is immune support: several Chinese trials have shown reductions in the frequency and severity of seasonal respiratory infections with extract supplementation over weeks to months, an indication consistent with the immunomodulatory activity documented in vitro (activation of NK cells, macrophages, and T lymphocytes, modulation of Th1/Th2 cytokines) and with millennia of traditional use.
In integrative oncology, astragalus has been used as an adjunct during chemotherapy and radiotherapy to reduce treatment-induced immunosuppression and improve tolerability and quality of life; several Chinese meta-analyses have documented reductions in leukopenia and improvements in immune parameters in cancer patients receiving astragalus-containing formulas, a traditional indication with modern clinical support, although the data are predominantly local and require independent validation in Western cohorts.
In chronic kidney disease, especially diabetic, several trials have shown reductions in proteinuria, improvements in glomerular filtration, and reductions in renal inflammatory markers with supplementation over months; astragalus is one of the main components of several Chinese formulas with clinical use in traditional nephrology, an indication with growing support but still with predominantly Asian data.
Cycloastragenol and other astragalosides have shown the ability to activate telomerase in cell cultures and animal studies, a property that has generated intense interest in anti-aging research; several premium commercial products (TA-65 and similar) offer cycloastragenol-enriched extracts with the promise of lengthening telomeres, but the clinical data in humans are preliminary, and whether telomere elongation translates into documented longevity benefits remains a matter of active scientific debate.
In mild to moderate heart failure and in ischemic heart disease, several Chinese trials have shown improvements in ejection fraction and clinical parameters with supplementation over months; the data are interesting but predominantly local and methodologically heterogeneous, so astragalus is positioned as an adjunct with growing support but not yet incorporated into Western cardiology guidelines.
The doses studied range from 500 to 3,000 milligrams daily of standardized dry root extract (ideally with a declared astragaloside content), divided into one or two doses with or without food; for immunomodulatory use, 1-2 g/day for 1-3 months; for oncology or kidney adjunct use, doses adjusted by the treating physician; traditional Chinese preparations use a root decoction at higher equivalent doses; premium products with enriched cycloastragenol are significantly more expensive, and their clinical superiority over the standard extract is unclear.
Generally well tolerated, with documented millennia-long use; the adverse effects described are rare and mild (digestive discomfort, occasionally rhinitis or skin rash in sensitive people); people with active autoimmune diseases (lupus, multiple sclerosis, rheumatoid arthritis in flare) should use caution because of the immunostimulatory activity, which could exacerbate autoimmune activity; those taking immunosuppressants (cyclosporine, tacrolimus, mycophenolate) should avoid it because of an expected pharmacodynamic interaction; in pregnancy and breastfeeding, data are limited and avoidance is recommended as a precaution; people with organ transplants should avoid it entirely because of the risk of rejection from immune stimulation.
Information, not medical advice. Scientific evidence reflects the quality of the studies.